z-logo
open-access-imgOpen Access
INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
Author(s) -
Patt Yehuda Z.,
Murad Waheed,
Fekrazad Mohammed H.,
Baron Ari D.,
Bansal Pranshu,
Boumber Yanis,
Steinberg Kim,
Lee SangJoon,
Bedrick Ed,
Du Ruofei,
Lee Fa Chyi
Publication year - 2017
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1138
Subject(s) - medicine , gastroenterology , hepatocellular carcinoma , gemcitabine , oxaliplatin , erlotinib , neutropenia , phases of clinical research , oncology , cancer , colorectal cancer , chemotherapy , epidermal growth factor receptor
Hepatocellular Carcinoma ( HCC ) incidence is increasing in the USA . Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer ( BDC ). Erlotinib (E) is an EGFR tyrosine kinase inhibitor ( TKI ) with known activity against both. We sought to evaluate the efficacy of the combination G+O+E. Patients with either of the two diagnosis were treated in a phase II trial. Simons 2 stage design was used. A disease‐control rate ( DCR ), complete response ( CR ) + partial response ( PR )+ stable disease ( SD ) at 24 weeks of ≤20% and >40% (P0 and P1 of 0.2 and 0.4, respectively) were set as undesirable (null) and desirable results. 26 HCC and 7 BDC patients were accrued. In HCC , 1 PR , 10 SD , and 9 PD s were seen. DCR in HCC was 42%. Among seven (7) patients with BDC , one patient was not evaluable; one achieved a long lasting PR , and five patients had SD and DCR was 86%. Median overall survival ( OS ) times and progression‐free survivals ( PFS ) were 196 and 149 days in HCC and 238 days and not reached in BDC . PFS at 26 weeks in HCC was 41% and at 21 weeks in BDC was 60%. Grade 3 toxicities in >5% of patients were fatigue (12.9%), neutropenia (9.6%), thrombocytopenia (9.6%), and diarrhea (6.4%). G+O+E exceeded both preset P0a and P1 of the primary objective with a PFS of 41% at 26 weeks for HCC and preliminary BDC data may warrant further investigations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here